| Name | Title | Contact Details |
|---|
Southeastern Medical Technologies is a Savannah, GA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Legacy Retirement Residence is a South Jordan, UT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
NextHealth Technologies (NHT), based in Denver CO, drives measurable medical cost reduction through a prescriptive analytics and consumer engagement platform. NextHealth’s proprietary SaaS platform integrates three foundational technologies - prescriptive analytics, behavioral economics, and multichannel consumer engagement. This end-to end, technology-enabled solution predicts risk reduction opportunities and then prescribes personalized member level actions or “nudges" to dramatically improve outcomes. NHT has been able to deliver a sustained and ground breaking 25% reduction in ER visits and over $17 per member per year in medical claims cost reduction for targeted commercial, ASO, and Medicaid populations. NHT offers over 30+ use cases including ER visit reduction, out-of-network reduction, and retention of high value individual members. NextHealth offers an at risk managed services contract based on 20% of causal claims savings. These results have led the company to be named by Gartner as one of the most innovative healthcare analytics vendors in the US. NHT’s multi-year software and managed services solution is currently contracted and supporting over 1.5 million members with some of the most reputable health plans in the country including: UnitedHealthcare, BlueCross BlueShield of Tennessee, and Colorado Access.
MolecularMD founders Brian Druker (lead clinical investigator for Gleevec, the first molecularly-targeted anticancer agent) and Sheridan G. Snyder (entrepreneur, founder of Genzyme and Upstate Biotechnology) came together with the mission of providing precise, standardized molecular testing for new oncology drugs. The company’s initial accomplishment was in developing and implementing the only standardized assay for quantification of BCR-ABL expression levels, which proved critical to pharmaceutical sponsors in satisfying regulators for approval of the second-generation ABL kinase inhibitors nilotinib (Tasigna, Novartis) and dasatinib (Sprycel, BMS). With that foundational success in supporting pivotal international studies with centralized, high-quality diagnostic services, MolecularMD has become a preferred provider of molecular diagnostics products and services to pharmaceutical and biotech drug developers. Capabilities range from specialty molecular testing services performed in MolecularMD’s centralized CLIA-certified and CAP-accredited laboratory, to development of FDA approved companion diagnostics to support new drug registrations.
American Health Care Software is a South Burlington, VT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.